Virtus ETF Advisers LLC increased its stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 15.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,847 shares of the biopharmaceutical company’s stock after buying an additional 2,307 shares during the period. Virtus ETF Advisers LLC’s holdings in Agios Pharmaceuticals were worth $840,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of AGIO. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Agios Pharmaceuticals by 27.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,666 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 779 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in Agios Pharmaceuticals by 481.6% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,280 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 2,716 shares during the period. Piedmont Investment Advisors Inc. purchased a new position in Agios Pharmaceuticals in the 1st quarter worth about $231,000. Creative Planning increased its stake in Agios Pharmaceuticals by 26.7% in the 2nd quarter. Creative Planning now owns 4,795 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 1,010 shares during the period. Finally, Cutler Group LP increased its stake in Agios Pharmaceuticals by 26.1% in the 2nd quarter. Cutler Group LP now owns 7,471 shares of the biopharmaceutical company’s stock worth $372,000 after buying an additional 1,546 shares during the period.
NASDAQ AGIO traded down $0.41 during trading on Friday, reaching $37.74. 721,932 shares of the company’s stock traded hands, compared to its average volume of 522,917. The company has a current ratio of 5.96, a quick ratio of 5.91 and a debt-to-equity ratio of 0.21. The company’s 50 day simple moving average is $40.70 and its two-hundred day simple moving average is $51.34. Agios Pharmaceuticals Inc has a 12-month low of $33.17 and a 12-month high of $79.17.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.87) EPS for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.17). The business had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $27.05 million. Agios Pharmaceuticals had a negative net margin of 383.05% and a negative return on equity of 59.89%. The company’s revenue for the quarter was down 35.1% on a year-over-year basis. During the same period last year, the business posted ($1.19) EPS. Equities analysts forecast that Agios Pharmaceuticals Inc will post -7.12 EPS for the current fiscal year.
Several research analysts recently commented on AGIO shares. BidaskClub raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday. Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Friday, May 31st. BMO Capital Markets began coverage on shares of Agios Pharmaceuticals in a research note on Thursday. They issued an “outperform” rating and a $45.00 price target on the stock. Royal Bank of Canada set a $89.00 target price on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Zacks Investment Research raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating and set a $46.00 target price on the stock in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $68.57.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
See Also: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.